首页 | 本学科首页   官方微博 | 高级检索  
检索        


Mutation screening of <Emphasis Type="Italic">mitofusin 2</Emphasis> in Charcot-Marie-Tooth disease type 2
Authors:III" target="_blank">Donald S McCorquodaleIII  Gladys Montenegro  Ainsley Peguero  Nicole Carlson  Fiorella Speziani  Justin Price  Sean W Taylor  Michel Melanson  Jeffery M Vance  Stephan Züchner
Institution:(1) Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Biomedical Research Building, Room 523, LC: M-860, 1501 NW 10th Avenue, Miami, FL 33136, USA;(2) Department of Neurology, Kingston General Hospital, Kingston, ON, Canada
Abstract:Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20–30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15–20% in CMT2.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号